Compare iShares S&P GSCI Commodity-Indexed Trust ETF (GSG) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares S&P GSCI Commodity-Indexed Trust ETF vs Vertex Pharmaceuticals Incorporated — how do they compare? iShares S&P GSCI Commodity-Indexed Trust ETF trades at $30.84, while Vertex Pharmaceuticals Incorporated trades at $483.49 (market cap $121.09B). Which is the better fit depends on your goals.
| GSG | VRTX | |
|---|---|---|
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $34.77 | $529.59 |
52-Week Low | $22.06 | $366.54 |
Market Cap | — | $121.09B |
Enterprise Value | — | $115.83B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSG, the iShares S&P GSCI Commodity-Indexed Trust ETF, trades at $30.85, down 0.48% on the day. Technical indicators show a bullish trend with moving averages strongly positive, though oscillators are neutral and short-term RSI signals suggest overbought conditions. Recent financial media highlights a thematic focus on commodities as a key market driver, with notable investors increasing exposure to the sector.
The outlook for GSG is tied to commodity price trends and broader economic developments. Investment opportunity lies in exposure to a constrained supply environment and inflation hedging. Primary risks include commodity price volatility, global economic slowdowns reducing demand, and the ETF's structure leading to tracking error or contango in futures markets.
Vertex Pharmaceuticals (VRTX) trades at $481.35, up 1.06% today, and is near its 52-week high. The stock shows a bullish technical signal with support at $471 and resistance at $482. Fundamentally, the company reported strong 2025 results with $12.0B revenue and $4.0B net income, though 2024 saw a loss. The recent $10B acquisition of Crinetics Pharmaceuticals aims to expand its endocrinology pipeline, potentially adding $5B in peak sales.
Outlook remains positive with analyst consensus at 'Buy' and a $538 price target, implying 12% upside. Key risks include integration challenges from the Crinetics deal and reliance on cystic fibrosis treatments. Earnings growth and pipeline expansion are primary catalysts, but investors should monitor execution on acquisitions and competitive pressures in biotech.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares S&P GSCI Commodity-Indexed Trust ETF
GSG is a diversified commodity ETF that tracks the S&P GSCI Total Return Index. It provides exposure to a broad basket of futures, including energy, metals, and agriculture, with a significant weighting toward the energy sector.
Read more on GSG →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
